By Michael Bloom
Publication Date: 2026-02-25 13:30:00
Here are the biggest calls on Wall Street on Wednesday: RBC initiates Eli Lilly at outperform RBC says the weight loss pharmaceutical maker is best positioned to fight obesity. “We favor Lilly ( TP $1,250) as our top momentum pick given its GLP-1 franchise strength and orforglipron oral launch.” Bank of America downgrades Molson Coors to underperform from neutral Bank of America says the brewer’s outlook was weaker than expected. “We lower our price objective to $42 from $50, based on an unchanged ~9x P/E multiple 2027 EPS estimates. TAP’s FY26 outlook was weaker than expected and, in our view, provided limited visibility into stabilizing volumes.” MoffettNathanson reiterates Apple as neutral MoffettNathanson raised its price target on the iPhone maker. “Thanks to positive earnings revisions in the wake of Apple’s strong December quarter, Apple’s valuation is now more reasonable, in our view. We are raising our target price to $270 (from $241). We maintain our neutral rating.” Rothschild & Co Redburn reiterates Nvidia as buy The firm said in an open letter to CEO Jensen Huang ahead of earnings that there are issues that Nvidia must address. “Six potential threats over the next 8 quarters. As we head into earnings and then GTC San Jose in March 2026, the market will be responsive to your perspective on six potential strategic threats.” Goldman Sachs reiterates Advanced Micro Devices as neutral Goldman raised its price target to $240 per share from $215 following the…
